gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · SVRAHealthcarePharmaceuticals

Savara Inc. (SVRA)

$4.66−1.89%
Close Nov 4, 2026 · split-adjusted
Nov 3, 2026$4.75▲ 11.24% in range
Nov 3, 2025Low $3.95 · High $6.94Nov 3, 2026
What changed · written from our data
As of Nov 4, 2026

Savara closed at $4.66 on Nov 4, down 1.89%, 32.9% below its 52-week closing high. Volume of 3.6M shares was 1.50× its 20-day average (above normal).

Split-adjusted performance: +0.2% over one month, -11.6% over six months, +9.1% over one year.

Short interest was 28.7M shares at the Oct 15 settlement, down 34.0% from the prior report (20.1% of float, 12.2 days to cover).

Market cap$957.4M205.5M shares
Revenue · quarter$0.00—
Diluted EPS$-0.16—
P/E · TTM—
Net margin—
Dividend yieldNone
52-week range3.95 – 6.94−32.9% from high
Volume3.6M1.50× 20-day avg
Volatility · 60d48.3%Annualised
Short % of float20.1%12.2 days to cover
Net cash$142.9MCash $173.0M
Next earnings—Not scheduled
Split-adjusted performance
1W −7.2%1M +0.2%3M −19.5%6M −11.6%YTD −22.7%1Y +9.1%3Y +27.0%5Y +305.2%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 420 companies (100 = best)

6-month momentum64
Revenue growth—
Net margin—
Value (low P/E)—
Size70

Industry medians: 6-month return −25.5%, revenue growth +6.2%, net margin −33.8%, P/E 16.1×.

Short interest

Details →
Shares short28.7M−34.0% vs prior
Days to cover12.2Settled Oct 15
% of float20.1%
Short vol. 10d53.4%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
SVRASavara$4.66−1.89%−11.6%———$957.4M
RIGLRigel Pharmaceuticals Inc. (New)$51.29+4.97%+92.3%−22.6%22.0%3.0$958.1MCompare
JBIOJade Biosciences$15.04+3.23%−40.2%———$956.5MCompare
ORICOric Pharmaceuticals$9.34−2.61%+0.4%———$968.1MCompare
SNDXSyndax Pharmaceuticals$10.45−26.87%−49.4%+81.6%−59.3%—$933.2MCompare
MLTXMoonLake Immunotherapeutics$11.56−1.20%−34.7%———$983.8MCompare
LTGOLatigo Biotherapeutics$14.04−3.64%————$930.8MCompare
ANROAlto Neuroscience$23.30+2.64%−4.9%———$914.3MCompare
CRVSCorvus Pharmaceuticals$10.57+7.53%−31.6%———$889.2MCompare

News about Savara

All news →
Savara Announces Chief Financial and Administrative Officer TransitionBenzinga · Jun 8, 2026NeutralSavara Announces Participation in the 2026 Jefferies Global Healthcare ConferenceBenzinga · May 27, 2026NeutralSavara Announces Participation in the H.C. Wainwright & Co. 4th Annual BioConnect Investor ConferenceBenzinga · May 11, 2026▲ PositiveSavara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)Benzinga · Mar 6, 2026▲ PositiveSavara Announces Participation in 2026 Citizens Life Sciences ConferenceBenzinga · Mar 4, 2026Neutral

Quick answers

What does Savara do?
Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases.
What is SVRA's market cap?
$957.44M, based on the Nov 4 close of $4.66.
Does Savara pay a dividend?
No regular cash dividend has been paid in the last year.
How much of SVRA is sold short?
28.7M shares, 20.1% of float, as of Oct 15, 2026.
What sector is SVRA in?
Healthcare, in the Pharmaceuticals industry.

About Savara

Savara Inc is a clinical-stage biopharmaceutical company. It is focused on rare respiratory diseases. It has one segment specialty pharmaceuticals within the respiratory system. The company's main product candidate, molgramostim, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP).

HQ: Austin, TX70 employeesListed Nov 18, 1996savarapharma.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology